Clinical Trial Update: Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation

View source ↗

Summary

A completed clinical trial evaluating Pulmicort Respules (budesonide) 0.25/0.5 for bronchial asthma. It is described as a Specific Clinical Experience Investiga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Pulmicort Respules (budesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchial Asthma | Status: COMPLETED